| scholarly article | Q13442814 |
| P50 | author | Elżbieta Tryniszewska | Q28672021 |
| Zdeněk Hel | Q39381883 | ||
| Mark G. Lewis | Q66732036 | ||
| P2093 | author name string | Barbara K Felber | |
| George N Pavlakis | |||
| Genoveffa Franchini | |||
| Janos Nacsa | |||
| Jim Tartaglia | |||
| Phillip D Markham | |||
| Wen-Po Tsai | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| Simian immunodeficiency virus | Q1890246 | ||
| P304 | page(s) | 85-96 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes | |
| P478 | volume | 176 |
| Q34034274 | A model for testing the immunogenicity of simian immunodeficiency virus and simian-human immunodeficiency virus vaccine candidates in mice. |
| Q34369139 | A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults |
| Q35785031 | A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe |
| Q35024266 | AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens |
| Q36667821 | Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS |
| Q30532861 | Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial |
| Q34428561 | Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides |
| Q46200257 | CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection |
| Q57259602 | CD8+ T-cell responses to different HIV proteins have discordant associations with viral load |
| Q61641053 | Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin |
| Q36961218 | Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection |
| Q37325709 | DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge |
| Q48036553 | Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers |
| Q35887146 | Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine |
| Q35826742 | HIV DNA Vaccine: Stepwise Improvements Make a Difference |
| Q22252422 | HIV infection: first battle decides the war |
| Q37344236 | HIV/AIDS vaccines: a need for new concepts? |
| Q36498186 | Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". |
| Q35995081 | Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology. |
| Q33402455 | Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239. |
| Q45398545 | Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus |
| Q37191899 | Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody |
| Q42131361 | Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques |
| Q33603602 | Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication. |
| Q51960480 | Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques. |
| Q28472020 | Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection |
| Q36844329 | Nef modulates the immunogenicity of Gag encoded in a non-infectious HIV DNA vaccine |
| Q36011269 | New paradigms for HIV/AIDS vaccine development |
| Q36971813 | Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans |
| Q26861148 | Nonhuman primate models for HIV/AIDS vaccine development |
| Q36483278 | Patterns of CD8+ immunodominance may influence the ability of Mamu-B*08-positive macaques to naturally control simian immunodeficiency virus SIVmac239 replication |
| Q51926211 | Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. |
| Q47776137 | Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice |
| Q36667917 | Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure |
| Q38786450 | Rare Control of SIVmac239 Infection in a Vaccinated Rhesus Macaque |
| Q38878282 | Recent HIV-1 infection in a high-risk Ugandan cohort: implications for Phase IIB test-of-concept HIV vaccine trials |
| Q36898836 | Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency |
| Q37547763 | Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques |
| Q33826671 | T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge |
| Q35658952 | Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. |
| Q94258415 | The Frequency of Vaccine-Induced T-Cell Responses Does Not Predict the Rate of Acquisition after Repeated Intrarectal SIVmac239 Challenges in Mamu-B*08+ Rhesus Macaques |
| Q61641064 | The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS |
| Q36760165 | Trivalent live attenuated influenza-simian immunodeficiency virus vaccines: efficacy and evolution of cytotoxic T lymphocyte escape in macaques |
| Q34651604 | Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239 |
| Q40113278 | Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques. |
| Q64284814 | Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine |
Search more.